[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fohNfUSJDIvFN-gHlKmGa4RXUaqL0hWJSPd3XHUu_2DE":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":75,"rows":82},"Instituto de Investigación Hospital Universitario La Paz",[4],103,false,11,5,16525,16,70,[14,17,19,21,24,26,29,31],{"name":15,"count":16},"Overweight",6,{"name":18,"count":9},"Cancer",{"name":20,"count":9},"Malnutrition",{"name":22,"count":23},"Nutrition Related Cancer",4,{"name":25,"count":23},"Breast Cancer",{"name":27,"count":28},"Ischemic Stroke",3,{"name":30,"count":28},"Healthy",{"name":32,"count":33},"Atrial Fibrillation",2,[35,40,45,50,55,60,65,70],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT06488898","Abdominal Aortic Aneurysm Stabilization With Truncal Cells: Controlled Clinical Trial With Historical Cohorts","2025-12-31","Allogeneic adipose tissue-derived mesenchymal stem cells",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT06556030","A Multicentre, Randomised, Single-blind, Controlled Protocol to Evaluate the Efficacy of Early Administration of Botulinum Toxin for Primary Midline Closure in Patients With Open Abdomen.","2026-06","Botulinum Toxin A",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT05304754","\"Phase I \u002F II Study on Infusion of Natural Killer Cells After Haploidentical Transplantation in Pediatric Patients\"","2026-06-30","NK cells stimulated ex vivo with IL-15",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT06701825","Effectiveness and Cost-effectiveness of a Pre-emptive Genotyping Strategy in Patients Receiving Tacrolimus","2026-10-01","Tacrolimus",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT07000526","Inhaled Sedation in Critically Ill Patients","2027-03","Isoflurane",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT07194057","\"A Privacy-protecting Environment for Child Transplants Health Related and Genomic Data Integration in the European Reference Network\"","2028-01","Whole genome sequencing",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT06878742","Dose-finding for Dobutamine During Transitional Circulation in Very Preterm Infants","2029-06","Intravenous dobutamine 5 mcg\u002Fkg\u002Fmin",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT06709469","Phase I Clinical Trial of CART Cell Therapy for Refractory\u002FRelapsed Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults","2030-06-01","Autologous CD19\u002FCD22 CAR T cells",[76,77,78,79,80,81],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[83,111,136,154,178,209,233,251,277,295,313,331,349,372,390,414,432,457,482,509,527,553,571,599,617,635,663,703,728,753,777,801,827,852,881,899,917,944,962,987,1005,1027,1052,1088,1113],{"intervention":44,"totalTrials":84,"cells":85},1,{"EARLY_PHASE1":86,"PHASE1":89,"PHASE2":91,"PHASE3":93,"PHASE4":95,"NA":109},{"trials":87,"activeCount":88},[],0,{"trials":90,"activeCount":88},[],{"trials":92,"activeCount":88},[],{"trials":94,"activeCount":88},[],{"trials":96,"activeCount":84,"soonestReadout":43},[97],{"nctId":41,"briefTitle":42,"status":98,"phases":99,"primaryCompletion":43,"completion":100,"start":101,"enrollment":102,"conditions":103,"interventions":108},"NOT_YET_RECRUITING",[80],"2026-12","2025-01",50,[104,105,106,107],"Botulinum Toxin Type A","Open Abdomen","Abdominal Wall","Clinical Trial",[44],{"trials":110,"activeCount":88},[],{"intervention":59,"totalTrials":84,"cells":112},{"EARLY_PHASE1":113,"PHASE1":115,"PHASE2":117,"PHASE3":119,"PHASE4":121,"NA":134},{"trials":114,"activeCount":88},[],{"trials":116,"activeCount":88},[],{"trials":118,"activeCount":88},[],{"trials":120,"activeCount":88},[],{"trials":122,"activeCount":84,"soonestReadout":58},[123],{"nctId":56,"briefTitle":57,"status":124,"phases":125,"primaryCompletion":58,"completion":126,"start":127,"enrollment":128,"conditions":129,"interventions":132},"RECRUITING",[80],"2027-12","2025-12-15",620,[130,131],"Sedation","Airway Extubation",[59,133],"Propofol",{"trials":135,"activeCount":88},[],{"intervention":133,"totalTrials":84,"cells":137},{"EARLY_PHASE1":138,"PHASE1":140,"PHASE2":142,"PHASE3":144,"PHASE4":146,"NA":152},{"trials":139,"activeCount":88},[],{"trials":141,"activeCount":88},[],{"trials":143,"activeCount":88},[],{"trials":145,"activeCount":88},[],{"trials":147,"activeCount":84,"soonestReadout":58},[148],{"nctId":56,"briefTitle":57,"status":124,"phases":149,"primaryCompletion":58,"completion":126,"start":127,"enrollment":128,"conditions":150,"interventions":151},[80],[130,131],[59,133],{"trials":153,"activeCount":88},[],{"intervention":54,"totalTrials":84,"cells":155},{"EARLY_PHASE1":156,"PHASE1":158,"PHASE2":160,"PHASE3":162,"PHASE4":164,"NA":176},{"trials":157,"activeCount":88},[],{"trials":159,"activeCount":88},[],{"trials":161,"activeCount":88},[],{"trials":163,"activeCount":88},[],{"trials":165,"activeCount":84,"soonestReadout":53},[166],{"nctId":51,"briefTitle":52,"status":124,"phases":167,"primaryCompletion":53,"completion":168,"start":169,"enrollment":170,"conditions":171,"interventions":175},[80],"2026-12-31","2025-06-02",114,[172,173,174],"Kidney Disease, Chronic","Transplant Recipient (Kidney)","Immunosuppression",[54,54],{"trials":177,"activeCount":88},[],{"intervention":39,"totalTrials":33,"cells":179},{"EARLY_PHASE1":180,"PHASE1":182,"PHASE2":184,"PHASE3":203,"PHASE4":205,"NA":207},{"trials":181,"activeCount":88},[],{"trials":183,"activeCount":88},[],{"trials":185,"activeCount":84,"soonestReadout":38},[186,193],{"nctId":36,"briefTitle":37,"status":124,"phases":187,"primaryCompletion":38,"completion":38,"start":188,"enrollment":189,"conditions":190,"interventions":192},[78],"2024-06-13",8,[191],"Aortic Aneurysm, Abdominal",[39],{"nctId":194,"briefTitle":195,"status":196,"phases":197,"primaryCompletion":198,"completion":198,"start":199,"enrollment":189,"conditions":200,"interventions":202},"NCT01914887","Allogeneic Adipose Tissue-derived Mesenchymal Stem Cells for the Induction of Remission in Ulcerative Colitis","UNKNOWN",[77,78],"2013-12","2013-06",[201],"Ulcerative Colitis",[39],{"trials":204,"activeCount":88},[],{"trials":206,"activeCount":88},[],{"trials":208,"activeCount":88},[],{"intervention":49,"totalTrials":84,"cells":210},{"EARLY_PHASE1":211,"PHASE1":213,"PHASE2":215,"PHASE3":227,"PHASE4":229,"NA":231},{"trials":212,"activeCount":88},[],{"trials":214,"activeCount":88},[],{"trials":216,"activeCount":84,"soonestReadout":48},[217],{"nctId":46,"briefTitle":47,"status":218,"phases":219,"primaryCompletion":48,"completion":220,"start":221,"enrollment":222,"conditions":223,"interventions":225},"ACTIVE_NOT_RECRUITING",[77,78],"2026-07","2020-11-30",18,[224],"High-risk Leukemias",[49,226],"Alloreactive NK cells",{"trials":228,"activeCount":88},[],{"trials":230,"activeCount":88},[],{"trials":232,"activeCount":88},[],{"intervention":226,"totalTrials":84,"cells":234},{"EARLY_PHASE1":235,"PHASE1":237,"PHASE2":239,"PHASE3":245,"PHASE4":247,"NA":249},{"trials":236,"activeCount":88},[],{"trials":238,"activeCount":88},[],{"trials":240,"activeCount":84,"soonestReadout":48},[241],{"nctId":46,"briefTitle":47,"status":218,"phases":242,"primaryCompletion":48,"completion":220,"start":221,"enrollment":222,"conditions":243,"interventions":244},[77,78],[224],[49,226],{"trials":246,"activeCount":88},[],{"trials":248,"activeCount":88},[],{"trials":250,"activeCount":88},[],{"intervention":69,"totalTrials":84,"cells":252},{"EARLY_PHASE1":253,"PHASE1":255,"PHASE2":257,"PHASE3":271,"PHASE4":273,"NA":275},{"trials":254,"activeCount":88},[],{"trials":256,"activeCount":88},[],{"trials":258,"activeCount":84,"soonestReadout":68},[259],{"nctId":66,"briefTitle":67,"status":124,"phases":260,"primaryCompletion":68,"completion":68,"start":261,"enrollment":262,"conditions":263,"interventions":266},[77,78],"2024-06-24",30,[264,265],"Infant, Premature, Diseases","Circulatory and Respiratory Physiological Phenomena",[69,267,268,269,270],"Intravenous dobutamine 7.5 mcg\u002Fkg\u002Fmin","Intravenous dobutamine 10 mcg\u002Fkg\u002Fmin","Intravenous dobutamine 12.5 mcg\u002Fkg\u002Fmin","Intravenous dobutamine 15 mcg\u002Fkg\u002Fmin",{"trials":272,"activeCount":88},[],{"trials":274,"activeCount":88},[],{"trials":276,"activeCount":88},[],{"intervention":267,"totalTrials":84,"cells":278},{"EARLY_PHASE1":279,"PHASE1":281,"PHASE2":283,"PHASE3":289,"PHASE4":291,"NA":293},{"trials":280,"activeCount":88},[],{"trials":282,"activeCount":88},[],{"trials":284,"activeCount":84,"soonestReadout":68},[285],{"nctId":66,"briefTitle":67,"status":124,"phases":286,"primaryCompletion":68,"completion":68,"start":261,"enrollment":262,"conditions":287,"interventions":288},[77,78],[264,265],[69,267,268,269,270],{"trials":290,"activeCount":88},[],{"trials":292,"activeCount":88},[],{"trials":294,"activeCount":88},[],{"intervention":268,"totalTrials":84,"cells":296},{"EARLY_PHASE1":297,"PHASE1":299,"PHASE2":301,"PHASE3":307,"PHASE4":309,"NA":311},{"trials":298,"activeCount":88},[],{"trials":300,"activeCount":88},[],{"trials":302,"activeCount":84,"soonestReadout":68},[303],{"nctId":66,"briefTitle":67,"status":124,"phases":304,"primaryCompletion":68,"completion":68,"start":261,"enrollment":262,"conditions":305,"interventions":306},[77,78],[264,265],[69,267,268,269,270],{"trials":308,"activeCount":88},[],{"trials":310,"activeCount":88},[],{"trials":312,"activeCount":88},[],{"intervention":269,"totalTrials":84,"cells":314},{"EARLY_PHASE1":315,"PHASE1":317,"PHASE2":319,"PHASE3":325,"PHASE4":327,"NA":329},{"trials":316,"activeCount":88},[],{"trials":318,"activeCount":88},[],{"trials":320,"activeCount":84,"soonestReadout":68},[321],{"nctId":66,"briefTitle":67,"status":124,"phases":322,"primaryCompletion":68,"completion":68,"start":261,"enrollment":262,"conditions":323,"interventions":324},[77,78],[264,265],[69,267,268,269,270],{"trials":326,"activeCount":88},[],{"trials":328,"activeCount":88},[],{"trials":330,"activeCount":88},[],{"intervention":270,"totalTrials":84,"cells":332},{"EARLY_PHASE1":333,"PHASE1":335,"PHASE2":337,"PHASE3":343,"PHASE4":345,"NA":347},{"trials":334,"activeCount":88},[],{"trials":336,"activeCount":88},[],{"trials":338,"activeCount":84,"soonestReadout":68},[339],{"nctId":66,"briefTitle":67,"status":124,"phases":340,"primaryCompletion":68,"completion":68,"start":261,"enrollment":262,"conditions":341,"interventions":342},[77,78],[264,265],[69,267,268,269,270],{"trials":344,"activeCount":88},[],{"trials":346,"activeCount":88},[],{"trials":348,"activeCount":88},[],{"intervention":74,"totalTrials":84,"cells":350},{"EARLY_PHASE1":351,"PHASE1":353,"PHASE2":364,"PHASE3":366,"PHASE4":368,"NA":370},{"trials":352,"activeCount":88},[],{"trials":354,"activeCount":84,"soonestReadout":73},[355],{"nctId":71,"briefTitle":72,"status":124,"phases":356,"primaryCompletion":73,"completion":357,"start":358,"enrollment":359,"conditions":360,"interventions":362},[77],"2030-12-01","2025-07-08",10,[361],"Precursor Cell Lymphoblastic Leukemia-Lymphoma",[74,363],"Allogeneic CART-NKG2D cells",{"trials":365,"activeCount":88},[],{"trials":367,"activeCount":88},[],{"trials":369,"activeCount":88},[],{"trials":371,"activeCount":88},[],{"intervention":363,"totalTrials":84,"cells":373},{"EARLY_PHASE1":374,"PHASE1":376,"PHASE2":382,"PHASE3":384,"PHASE4":386,"NA":388},{"trials":375,"activeCount":88},[],{"trials":377,"activeCount":84,"soonestReadout":73},[378],{"nctId":71,"briefTitle":72,"status":124,"phases":379,"primaryCompletion":73,"completion":357,"start":358,"enrollment":359,"conditions":380,"interventions":381},[77],[361],[74,363],{"trials":383,"activeCount":88},[],{"trials":385,"activeCount":88},[],{"trials":387,"activeCount":88},[],{"trials":389,"activeCount":88},[],{"intervention":64,"totalTrials":84,"cells":391},{"EARLY_PHASE1":392,"PHASE1":394,"PHASE2":396,"PHASE3":398,"PHASE4":400,"NA":402},{"trials":393,"activeCount":88},[],{"trials":395,"activeCount":88},[],{"trials":397,"activeCount":88},[],{"trials":399,"activeCount":88},[],{"trials":401,"activeCount":88},[],{"trials":403,"activeCount":84,"soonestReadout":63},[404],{"nctId":61,"briefTitle":62,"status":98,"phases":405,"primaryCompletion":63,"completion":63,"start":406,"enrollment":407,"conditions":408,"interventions":412},[],"2025-09-30",200,[409,410,411],"Transplant Complication","Kidney Transplant","Liver Transplant",[64,413],"Polygenic Risk Score Calculation",{"intervention":413,"totalTrials":84,"cells":415},{"EARLY_PHASE1":416,"PHASE1":418,"PHASE2":420,"PHASE3":422,"PHASE4":424,"NA":426},{"trials":417,"activeCount":88},[],{"trials":419,"activeCount":88},[],{"trials":421,"activeCount":88},[],{"trials":423,"activeCount":88},[],{"trials":425,"activeCount":88},[],{"trials":427,"activeCount":84,"soonestReadout":63},[428],{"nctId":61,"briefTitle":62,"status":98,"phases":429,"primaryCompletion":63,"completion":63,"start":406,"enrollment":407,"conditions":430,"interventions":431},[],[409,410,411],[64,413],{"intervention":433,"totalTrials":84,"cells":434},"Second-line systemic treatment",{"EARLY_PHASE1":435,"PHASE1":437,"PHASE2":439,"PHASE3":441,"PHASE4":443,"NA":455},{"trials":436,"activeCount":88},[],{"trials":438,"activeCount":88},[],{"trials":440,"activeCount":88},[],{"trials":442,"activeCount":88},[],{"trials":444,"activeCount":88},[445],{"nctId":446,"briefTitle":447,"status":196,"phases":448,"primaryCompletion":449,"completion":449,"start":450,"enrollment":451,"conditions":452,"interventions":454},"NCT06366932","Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models",[80],"2025-09","2023-09-25",150,[453],"Atopic Dermatitis",[433],{"trials":456,"activeCount":88},[],{"intervention":458,"totalTrials":84,"cells":459},"Cyclosporin A",{"EARLY_PHASE1":460,"PHASE1":462,"PHASE2":464,"PHASE3":466,"PHASE4":468,"NA":480},{"trials":461,"activeCount":88},[],{"trials":463,"activeCount":88},[],{"trials":465,"activeCount":88},[],{"trials":467,"activeCount":88},[],{"trials":469,"activeCount":88},[470],{"nctId":471,"briefTitle":472,"status":196,"phases":473,"primaryCompletion":474,"completion":475,"start":476,"enrollment":477,"conditions":478,"interventions":479},"NCT05692843","Optimization of Cyclosporin in Atopic Dermatitis Through Multiomic Predictive Models of Treatment Response",[80],"2023-11","2024-07","2022-10-10",100,[453],[458],{"trials":481,"activeCount":88},[],{"intervention":483,"totalTrials":84,"cells":484},"Voriconazole preemptive genotyping strategy",{"EARLY_PHASE1":485,"PHASE1":487,"PHASE2":489,"PHASE3":491,"PHASE4":493,"NA":507},{"trials":486,"activeCount":88},[],{"trials":488,"activeCount":88},[],{"trials":490,"activeCount":88},[],{"trials":492,"activeCount":88},[],{"trials":494,"activeCount":88},[495],{"nctId":496,"briefTitle":497,"status":196,"phases":498,"primaryCompletion":499,"completion":500,"start":501,"enrollment":502,"conditions":503,"interventions":505},"NCT04238884","Effectiveness and Efficiency of a Voriconazole Preemptive Genotyping Strategy",[80],"2020-01-18","2022-12-31","2020-01-02",146,[504],"Invasive Fungal Infections",[483,506],"Voriconazole clinical practice",{"trials":508,"activeCount":88},[],{"intervention":506,"totalTrials":84,"cells":510},{"EARLY_PHASE1":511,"PHASE1":513,"PHASE2":515,"PHASE3":517,"PHASE4":519,"NA":525},{"trials":512,"activeCount":88},[],{"trials":514,"activeCount":88},[],{"trials":516,"activeCount":88},[],{"trials":518,"activeCount":88},[],{"trials":520,"activeCount":88},[521],{"nctId":496,"briefTitle":497,"status":196,"phases":522,"primaryCompletion":499,"completion":500,"start":501,"enrollment":502,"conditions":523,"interventions":524},[80],[504],[483,506],{"trials":526,"activeCount":88},[],{"intervention":528,"totalTrials":84,"cells":529},"Ibuprofen in continuous (24 hours) iv infusion and EchoG",{"EARLY_PHASE1":530,"PHASE1":532,"PHASE2":534,"PHASE3":536,"PHASE4":549,"NA":551},{"trials":531,"activeCount":88},[],{"trials":533,"activeCount":88},[],{"trials":535,"activeCount":88},[],{"trials":537,"activeCount":88},[538],{"nctId":539,"briefTitle":540,"status":196,"phases":541,"primaryCompletion":542,"completion":221,"start":543,"enrollment":544,"conditions":545,"interventions":547},"NCT04282941","Clinical Trial to Evaluate Two Guidelines for the Administration of Ibuprofen in the Treatment of Persistent Ductus Arteriosus Eco-guided: Impact in the Intestinal Prognosis",[79],"2020-01-30","2017-02-20",180,[546],"Persistent Ductus Arteriosus",[528,548],"IV bolus Ibuprofen slow (15 minutes) and EchoG",{"trials":550,"activeCount":88},[],{"trials":552,"activeCount":88},[],{"intervention":548,"totalTrials":84,"cells":554},{"EARLY_PHASE1":555,"PHASE1":557,"PHASE2":559,"PHASE3":561,"PHASE4":567,"NA":569},{"trials":556,"activeCount":88},[],{"trials":558,"activeCount":88},[],{"trials":560,"activeCount":88},[],{"trials":562,"activeCount":88},[563],{"nctId":539,"briefTitle":540,"status":196,"phases":564,"primaryCompletion":542,"completion":221,"start":543,"enrollment":544,"conditions":565,"interventions":566},[79],[546],[528,548],{"trials":568,"activeCount":88},[],{"trials":570,"activeCount":88},[],{"intervention":572,"totalTrials":84,"cells":573},"Emtricitabine\u002FTenofovir Disoproxil Fumarate 200 MG-245 MG Oral Tablet [TRUVADA]",{"EARLY_PHASE1":574,"PHASE1":576,"PHASE2":578,"PHASE3":580,"PHASE4":595,"NA":597},{"trials":575,"activeCount":88},[],{"trials":577,"activeCount":88},[],{"trials":579,"activeCount":88},[],{"trials":581,"activeCount":88},[582],{"nctId":583,"briefTitle":584,"status":585,"phases":586,"primaryCompletion":587,"completion":587,"start":588,"enrollment":589,"conditions":590,"interventions":592},"NCT04890626","Clinical Trial to Evaluate the Efficacy of Different Treatments in Patients With COVID-19","COMPLETED",[79],"2023-07-17","2020-04-04",356,[591],"SARS-CoV-2 Infection",[572,593,594],"Baricitinib + dexamethasone","Dexamethasone",{"trials":596,"activeCount":88},[],{"trials":598,"activeCount":88},[],{"intervention":593,"totalTrials":84,"cells":600},{"EARLY_PHASE1":601,"PHASE1":603,"PHASE2":605,"PHASE3":607,"PHASE4":613,"NA":615},{"trials":602,"activeCount":88},[],{"trials":604,"activeCount":88},[],{"trials":606,"activeCount":88},[],{"trials":608,"activeCount":88},[609],{"nctId":583,"briefTitle":584,"status":585,"phases":610,"primaryCompletion":587,"completion":587,"start":588,"enrollment":589,"conditions":611,"interventions":612},[79],[591],[572,593,594],{"trials":614,"activeCount":88},[],{"trials":616,"activeCount":88},[],{"intervention":594,"totalTrials":84,"cells":618},{"EARLY_PHASE1":619,"PHASE1":621,"PHASE2":623,"PHASE3":625,"PHASE4":631,"NA":633},{"trials":620,"activeCount":88},[],{"trials":622,"activeCount":88},[],{"trials":624,"activeCount":88},[],{"trials":626,"activeCount":88},[627],{"nctId":583,"briefTitle":584,"status":585,"phases":628,"primaryCompletion":587,"completion":587,"start":588,"enrollment":589,"conditions":629,"interventions":630},[79],[591],[572,593,594],{"trials":632,"activeCount":88},[],{"trials":634,"activeCount":88},[],{"intervention":636,"totalTrials":84,"cells":637},"Melatonin 2mg",{"EARLY_PHASE1":638,"PHASE1":640,"PHASE2":642,"PHASE3":644,"PHASE4":659,"NA":661},{"trials":639,"activeCount":88},[],{"trials":641,"activeCount":88},[],{"trials":643,"activeCount":88},[],{"trials":645,"activeCount":88},[646],{"nctId":647,"briefTitle":648,"status":585,"phases":649,"primaryCompletion":650,"completion":651,"start":652,"enrollment":653,"conditions":654,"interventions":658},"NCT04353128","Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers.",[78,79],"2020-10-01","2020-12-01","2020-04-20",450,[655,656,657],"Covid19","SARS-CoV 2","Coronavirus Infection",[636],{"trials":660,"activeCount":88},[],{"trials":662,"activeCount":88},[],{"intervention":664,"totalTrials":28,"cells":665},"Adipose-derived stem cells without expanded",{"EARLY_PHASE1":666,"PHASE1":668,"PHASE2":670,"PHASE3":697,"PHASE4":699,"NA":701},{"trials":667,"activeCount":88},[],{"trials":669,"activeCount":88},[],{"trials":671,"activeCount":88},[672,681,690],{"nctId":673,"briefTitle":674,"status":196,"phases":675,"primaryCompletion":676,"completion":198,"start":677,"enrollment":359,"conditions":678,"interventions":680},"NCT01586715","Stem Cells Treatment for Extremely Complex Fistulae (HULPCIR)",[78],"2013-05","2012-03",[679],"Extremely Complex Perianal Fistulae",[664],{"nctId":682,"briefTitle":683,"status":196,"phases":684,"primaryCompletion":685,"completion":198,"start":686,"enrollment":359,"conditions":687,"interventions":689},"NCT01584713","Stromal Vascular Fraction (SVF) for Treatment of Enterocutaneous Fistula (HULPUTC)",[77,78],"2012-07","2011-12",[688],"Enterocutaneous Fistula",[664],{"nctId":691,"briefTitle":692,"status":196,"phases":693,"primaryCompletion":685,"completion":198,"start":686,"enrollment":359,"conditions":694,"interventions":696},"NCT01548092","Stromal Vascular Fraction (SVF) for Treatment of Recto-vaginal Fistula",[77,78],[695],"Recto-vaginal Fistula",[664],{"trials":698,"activeCount":88},[],{"trials":700,"activeCount":88},[],{"trials":702,"activeCount":88},[],{"intervention":704,"totalTrials":84,"cells":705},"Thymoglobulin",{"EARLY_PHASE1":706,"PHASE1":708,"PHASE2":710,"PHASE3":722,"PHASE4":724,"NA":726},{"trials":707,"activeCount":88},[],{"trials":709,"activeCount":88},[],{"trials":711,"activeCount":88},[712],{"nctId":713,"briefTitle":714,"status":585,"phases":715,"primaryCompletion":716,"completion":716,"start":717,"enrollment":718,"conditions":719,"interventions":721},"NCT01939171","Thymoglobulin in Cadaver Donor",[78],"2012-02","2010-06",20,[720],"Prevention of Kidney Injury Associated With Brain Death",[704],{"trials":723,"activeCount":88},[],{"trials":725,"activeCount":88},[],{"trials":727,"activeCount":88},[],{"intervention":729,"totalTrials":84,"cells":730},"mesenchymal stem cells derived from bone marrow",{"EARLY_PHASE1":731,"PHASE1":733,"PHASE2":735,"PHASE3":747,"PHASE4":749,"NA":751},{"trials":732,"activeCount":88},[],{"trials":734,"activeCount":88},[],{"trials":736,"activeCount":88},[737],{"nctId":738,"briefTitle":739,"status":196,"phases":740,"primaryCompletion":741,"completion":741,"start":742,"enrollment":743,"conditions":744,"interventions":746},"NCT04153630","Safety Study and Preliminary Efficacy of Infusion Haploidentical Mesenchymal Stem Cells Derived From Bone Marrow for Treating Recessive Dystrophic Epidermolysis Bullosa",[77,78],"2021-03","2018-05-17",9,[745],"Epidermolysis Bullosa Dystrophica, Recessive",[729],{"trials":748,"activeCount":88},[],{"trials":750,"activeCount":88},[],{"trials":752,"activeCount":88},[],{"intervention":754,"totalTrials":84,"cells":755},"Allogenic mesenchymal stem cells from adipose tissue",{"EARLY_PHASE1":756,"PHASE1":758,"PHASE2":760,"PHASE3":771,"PHASE4":773,"NA":775},{"trials":757,"activeCount":88},[],{"trials":759,"activeCount":88},[],{"trials":761,"activeCount":88},[762],{"nctId":763,"briefTitle":764,"status":585,"phases":765,"primaryCompletion":766,"completion":766,"start":767,"enrollment":768,"conditions":769,"interventions":770},"NCT01678534","Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial",[78],"2017-12","2014-09",19,[27],[754],{"trials":772,"activeCount":88},[],{"trials":774,"activeCount":88},[],{"trials":776,"activeCount":88},[],{"intervention":778,"totalTrials":84,"cells":779},"Expanded adipose-derived stem cells",{"EARLY_PHASE1":780,"PHASE1":782,"PHASE2":784,"PHASE3":795,"PHASE4":797,"NA":799},{"trials":781,"activeCount":88},[],{"trials":783,"activeCount":88},[],{"trials":785,"activeCount":88},[786],{"nctId":787,"briefTitle":788,"status":196,"phases":789,"primaryCompletion":198,"completion":790,"start":791,"enrollment":189,"conditions":792,"interventions":794},"NCT01808378","Stem Cells Treatment for Bilateral Limbic Associated Keratopathy (HULPOFT)",[78],"2014-12","2013-02",[793],"Keratopathy",[778],{"trials":796,"activeCount":88},[],{"trials":798,"activeCount":88},[],{"trials":800,"activeCount":88},[],{"intervention":802,"totalTrials":84,"cells":803},"T memory cells and NK cells",{"EARLY_PHASE1":804,"PHASE1":806,"PHASE2":808,"PHASE3":821,"PHASE4":823,"NA":825},{"trials":805,"activeCount":88},[],{"trials":807,"activeCount":88},[],{"trials":809,"activeCount":88},[810],{"nctId":811,"briefTitle":812,"status":585,"phases":813,"primaryCompletion":814,"completion":815,"start":816,"enrollment":817,"conditions":818,"interventions":820},"NCT04578210","Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia",[77,78],"2022-01-13","2022-03-30","2020-09-04",84,[819],"Corona Virus Infection",[802],{"trials":822,"activeCount":88},[],{"trials":824,"activeCount":88},[],{"trials":826,"activeCount":88},[],{"intervention":828,"totalTrials":84,"cells":829},"Adipose-derived expanded stem cells",{"EARLY_PHASE1":830,"PHASE1":832,"PHASE2":834,"PHASE3":846,"PHASE4":848,"NA":850},{"trials":831,"activeCount":88},[],{"trials":833,"activeCount":88},[],{"trials":835,"activeCount":88},[836],{"nctId":837,"briefTitle":838,"status":196,"phases":839,"primaryCompletion":840,"completion":841,"start":842,"enrollment":359,"conditions":843,"interventions":845},"NCT01804153","Stem Cells Tratment for the Local Feminine Stress Urinary Incontinence Treatment (HULPURO)",[77,78],"2013-10","2014-04","2012-09",[844],"Urinary Incontinence",[828],{"trials":847,"activeCount":88},[],{"trials":849,"activeCount":88},[],{"trials":851,"activeCount":88},[],{"intervention":853,"totalTrials":84,"cells":854},"cyclophosphamide",{"EARLY_PHASE1":855,"PHASE1":857,"PHASE2":859,"PHASE3":875,"PHASE4":877,"NA":879},{"trials":856,"activeCount":88},[],{"trials":858,"activeCount":88},[],{"trials":860,"activeCount":88},[861],{"nctId":862,"briefTitle":863,"status":585,"phases":864,"primaryCompletion":865,"completion":865,"start":866,"enrollment":867,"conditions":868,"interventions":872},"NCT02763475","NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children\u002FAdolescents",[78],"2020-08","2016-05",7,[869,870,871],"Acute Myeloid Leukemia","Leukemia","Myeloid Leukemia",[853,873,874],"Fludarabine","IL-2",{"trials":876,"activeCount":88},[],{"trials":878,"activeCount":88},[],{"trials":880,"activeCount":88},[],{"intervention":873,"totalTrials":84,"cells":882},{"EARLY_PHASE1":883,"PHASE1":885,"PHASE2":887,"PHASE3":893,"PHASE4":895,"NA":897},{"trials":884,"activeCount":88},[],{"trials":886,"activeCount":88},[],{"trials":888,"activeCount":88},[889],{"nctId":862,"briefTitle":863,"status":585,"phases":890,"primaryCompletion":865,"completion":865,"start":866,"enrollment":867,"conditions":891,"interventions":892},[78],[869,870,871],[853,873,874],{"trials":894,"activeCount":88},[],{"trials":896,"activeCount":88},[],{"trials":898,"activeCount":88},[],{"intervention":874,"totalTrials":84,"cells":900},{"EARLY_PHASE1":901,"PHASE1":903,"PHASE2":905,"PHASE3":911,"PHASE4":913,"NA":915},{"trials":902,"activeCount":88},[],{"trials":904,"activeCount":88},[],{"trials":906,"activeCount":88},[907],{"nctId":862,"briefTitle":863,"status":585,"phases":908,"primaryCompletion":865,"completion":865,"start":866,"enrollment":867,"conditions":909,"interventions":910},[78],[869,870,871],[853,873,874],{"trials":912,"activeCount":88},[],{"trials":914,"activeCount":88},[],{"trials":916,"activeCount":88},[],{"intervention":918,"totalTrials":84,"cells":919},"Dolutegravir",{"EARLY_PHASE1":920,"PHASE1":922,"PHASE2":924,"PHASE3":938,"PHASE4":940,"NA":942},{"trials":921,"activeCount":88},[],{"trials":923,"activeCount":88},[],{"trials":925,"activeCount":88},[926],{"nctId":927,"briefTitle":928,"status":196,"phases":929,"primaryCompletion":930,"completion":931,"start":932,"enrollment":933,"conditions":934,"interventions":936},"NCT03539224","Antiretroviral Treatment Guided by Proviral Genotype: Pilot Trial of Proof of Concept.",[78],"2021-05-31","2021-07-31","2017-11-02",41,[935],"HIV-1-infection",[918,937],"Lamivudine",{"trials":939,"activeCount":88},[],{"trials":941,"activeCount":88},[],{"trials":943,"activeCount":88},[],{"intervention":937,"totalTrials":84,"cells":945},{"EARLY_PHASE1":946,"PHASE1":948,"PHASE2":950,"PHASE3":956,"PHASE4":958,"NA":960},{"trials":947,"activeCount":88},[],{"trials":949,"activeCount":88},[],{"trials":951,"activeCount":88},[952],{"nctId":927,"briefTitle":928,"status":196,"phases":953,"primaryCompletion":930,"completion":931,"start":932,"enrollment":933,"conditions":954,"interventions":955},[78],[935],[918,937],{"trials":957,"activeCount":88},[],{"trials":959,"activeCount":88},[],{"trials":961,"activeCount":88},[],{"intervention":963,"totalTrials":84,"cells":964},"Lactitol",{"EARLY_PHASE1":965,"PHASE1":967,"PHASE2":969,"PHASE3":981,"PHASE4":983,"NA":985},{"trials":966,"activeCount":88},[],{"trials":968,"activeCount":88},[],{"trials":970,"activeCount":88},[971],{"nctId":972,"briefTitle":973,"status":196,"phases":974,"primaryCompletion":975,"completion":975,"start":976,"enrollment":718,"conditions":977,"interventions":979},"NCT02307383","Pilot Study of the Effectiveness of Probiotics and Lactitol for the Decolonization of OXA-48 (Carbapenemase) Producing Klebsiella Pneumoniae Among Rectal Carriers",[78],"2015-10","2014-10",[978],"Bacterial Colonization",[963,980],"Lactobacillus",{"trials":982,"activeCount":88},[],{"trials":984,"activeCount":88},[],{"trials":986,"activeCount":88},[],{"intervention":980,"totalTrials":84,"cells":988},{"EARLY_PHASE1":989,"PHASE1":991,"PHASE2":993,"PHASE3":999,"PHASE4":1001,"NA":1003},{"trials":990,"activeCount":88},[],{"trials":992,"activeCount":88},[],{"trials":994,"activeCount":88},[995],{"nctId":972,"briefTitle":973,"status":196,"phases":996,"primaryCompletion":975,"completion":975,"start":976,"enrollment":718,"conditions":997,"interventions":998},[78],[978],[963,980],{"trials":1000,"activeCount":88},[],{"trials":1002,"activeCount":88},[],{"trials":1004,"activeCount":88},[],{"intervention":1006,"totalTrials":84,"cells":1007},"Inject of Autologous Adipose-derived stem cells",{"EARLY_PHASE1":1008,"PHASE1":1010,"PHASE2":1012,"PHASE3":1021,"PHASE4":1023,"NA":1025},{"trials":1009,"activeCount":88},[],{"trials":1011,"activeCount":88},[],{"trials":1013,"activeCount":88},[1014],{"nctId":1015,"briefTitle":1016,"status":585,"phases":1017,"primaryCompletion":791,"completion":791,"start":1018,"enrollment":359,"conditions":1019,"interventions":1020},"NCT01799694","Stem Cells Treatment for the Local Urinary Incontinence After a Radical Prostate Cancer Surgery (HULPURO)",[78],"2011-07",[844],[1006],{"trials":1022,"activeCount":88},[],{"trials":1024,"activeCount":88},[],{"trials":1026,"activeCount":88},[],{"intervention":1028,"totalTrials":84,"cells":1029},"COMIRNATY",{"EARLY_PHASE1":1030,"PHASE1":1032,"PHASE2":1034,"PHASE3":1046,"PHASE4":1048,"NA":1050},{"trials":1031,"activeCount":88},[],{"trials":1033,"activeCount":88},[],{"trials":1035,"activeCount":88},[1036],{"nctId":1037,"briefTitle":1038,"status":196,"phases":1039,"primaryCompletion":1040,"completion":1041,"start":1042,"enrollment":1043,"conditions":1044,"interventions":1045},"NCT05378191","Vaccination With COMIRNATY in Subjects With a VAXZEVRIA First Dose",[78],"2022-08-22","2022-12-30","2021-04-22",600,[655],[1028],{"trials":1047,"activeCount":88},[],{"trials":1049,"activeCount":88},[],{"trials":1051,"activeCount":88},[],{"intervention":1053,"totalTrials":33,"cells":1054},"Psychotropic treatment",{"EARLY_PHASE1":1055,"PHASE1":1057,"PHASE2":1059,"PHASE3":1061,"PHASE4":1063,"NA":1065},{"trials":1056,"activeCount":88},[],{"trials":1058,"activeCount":88},[],{"trials":1060,"activeCount":88},[],{"trials":1062,"activeCount":88},[],{"trials":1064,"activeCount":88},[],{"trials":1066,"activeCount":88},[1067,1078],{"nctId":1068,"briefTitle":1069,"status":585,"phases":1070,"primaryCompletion":1071,"completion":1071,"start":1072,"enrollment":1073,"conditions":1074,"interventions":1077},"NCT03434405","Mindfulness-based Social Cognition Training for Psychosis (SocialMind): A Feasibility Study",[81],"2018-06-30","2018-02-25",27,[1075,1076],"Schizophrenia and Disorders With Psychotic Feature","Psychotic Episode",[1053],{"nctId":1079,"briefTitle":1080,"status":585,"phases":1081,"primaryCompletion":1082,"completion":1082,"start":1083,"enrollment":1084,"conditions":1085,"interventions":1087},"NCT03309475","Effectiveness of a Mindfulness-based Group Training Addressing Social Cognition in First Episode Psychosis (AGES-Mind)",[81],"2023-01-31","2018-09-01",59,[1086,1076],"Schizophrenia and Disorders With Psychotic Features",[1053],{"intervention":1089,"totalTrials":84,"cells":1090},"Acenocoumarol",{"EARLY_PHASE1":1091,"PHASE1":1093,"PHASE2":1095,"PHASE3":1097,"PHASE4":1099,"NA":1101},{"trials":1092,"activeCount":88},[],{"trials":1094,"activeCount":88},[],{"trials":1096,"activeCount":88},[],{"trials":1098,"activeCount":88},[],{"trials":1100,"activeCount":88},[],{"trials":1102,"activeCount":88},[1103],{"nctId":1104,"briefTitle":1105,"status":585,"phases":1106,"primaryCompletion":840,"completion":840,"start":1107,"enrollment":1108,"conditions":1109,"interventions":1112},"NCT03015025","Pharmacogenetic Dosage Algorithm for Acenocoumarol",[],"2011-10",340,[32,1110,1111],"Venous Thromboses","Cardiac Valve Disease",[1089],{"intervention":1114,"totalTrials":84,"cells":1115},"Opioid",{"EARLY_PHASE1":1116,"PHASE1":1118,"PHASE2":1120,"PHASE3":1122,"PHASE4":1124,"NA":1126},{"trials":1117,"activeCount":88},[],{"trials":1119,"activeCount":88},[],{"trials":1121,"activeCount":88},[],{"trials":1123,"activeCount":88},[],{"trials":1125,"activeCount":88},[],{"trials":1127,"activeCount":88},[1128],{"nctId":1129,"briefTitle":1130,"status":585,"phases":1131,"primaryCompletion":1132,"completion":1132,"start":1133,"enrollment":1134,"conditions":1135,"interventions":1139},"NCT05448586","Opioid Free Anaesthesia in Oncologic Gynaecological Surgery: Is There Any Benefit?",[],"2021-01-30","2019-02-02",132,[1136,1137,1138,25],"Cervix Cancer","Endometrial Cancer","Ovarian Cancer",[1114]]